A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

For patients with mCSPC with homologous recombination repair gene alterations, the addition of niraparib to abiraterone acetate and prednisone is beneficial.

Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

Professor Gerhardt Attard, who led the study, said the new combination could “significantly prolong life expectancy” in patients with mutations in their homologous recombination repair (HRR) genes.

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...